Stay updated on AVA6000 in Solid Tumours Clinical Trial
Sign up to get notified when there's something new on the AVA6000 in Solid Tumours Clinical Trial page.

Latest updates to the AVA6000 in Solid Tumours Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check37 days agoChange Detected- Revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 with no changes to core study content or page data.SummaryDifference0.0%

- Check66 days agoChange DetectedThe study page appears unchanged in core content such as eligibility criteria and locations; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check73 days agoChange DetectedAdded details of the Phase 1a 3+3 dose-escalation design for AVA6000 with Q3W and Q2W schedules and the Phase 1b dose expansion with an RDE-1 cohort to identify the optimal biologic dose. It also notes AVA6000 as a FAP-activated doxorubicin and updates the cardiac safety assessment to include cumulative exposure to doxorubicin.SummaryDifference1%

- Check80 days agoChange DetectedAdded a site-wide notice about government funding status and NIH CC operations, and updated CMS to version v3.4.1. The previous CMS version v3.4.0 was removed.SummaryDifference0.4%

Stay in the know with updates to AVA6000 in Solid Tumours Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AVA6000 in Solid Tumours Clinical Trial page.